Peripheral blood stem cell transplantation; an update.
Patients with a number of different malignancies have been treated with high-dose chemotherapy and peripheral blood stem cell transplantation (PBSCT). PBSC already replaced bone marrow as the source of autologous hematopoietic progenitor support. This is due to ease of collection, rapid engraftment and less possibility of tumor cell contamination in the graft. Furthermore, allogeneic transplantation of granulocyte colony-stimulating factor (G-CSF) mobilized PBSC is now being increasingly performed. Recent advance of clinical PBSCT and new strategies are stressed in this review. New strategies include CD 34+cell purification, ex vivo expansion of PBSC and PBSC as a target cell for gene therapy. Major future advance may occur better understanding of the mechanism of mobilization and the biology of PBSC.
Watanabe
T
T
Department of Pediatrics, University of Tokushima School of Medicine, Japan.
Takaue
Y
Y
Kawano
Y
Y
D018380:Hematopoietic Stem Cell Transplantation / Q000639:trends*; D006801:Humans; D009369:Neoplasms / Q000628:therapy*